{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:36Z","timestamp":1790790696745,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.advms.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T18:30:25Z","timestamp":1439404225000},"page":"349-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["CXCL10 in psoriasis"],"prefix":"10.1016","volume":"60","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ruffilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clodoveo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0470","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0475","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.advms.2015.07.011_bib0480","series-title":"Dermatology: illustrated study guide and comprehensive board review","author":"Sima","year":"2012"},{"issue":"10","key":"10.1016\/j.advms.2015.07.011_bib0485","first-page":"2026","article-title":"High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis","volume":"33","author":"Antonelli","year":"2006","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0490","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cytogfr.2010.10.007","article-title":"Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease","volume":"21","author":"Ouyang","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4\u20135","key":"10.1016\/j.advms.2015.07.011_bib0495","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.advms.2015.07.011_bib0500","doi-asserted-by":"crossref","DOI":"10.12968\/bjcn.2012.17.11.524","article-title":"Psoriasis: symptoms, treatments and its impact on quality of life","volume":"17","author":"Parrish","year":"2012","journal-title":"Br J Community Nurs"},{"key":"10.1016\/j.advms.2015.07.011_bib0505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/DDDT.S32713","article-title":"New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast","volume":"7","author":"Palfreeman","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0510","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0515","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tig.2010.06.006","article-title":"Psoriasis genetics: breaking the barrier","volume":"26","author":"Roberson","year":"2010","journal-title":"Trends Genet"},{"issue":"3","key":"10.1016\/j.advms.2015.07.011_bib0520","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clindermatol.2011.08.025","article-title":"Epidermal barrier function and systemic diseases","volume":"30","author":"Ramos-e-Silva","year":"2012","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0525","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0625.2012.01459.x","article-title":"LL-37: a defense molecule with a potential role in psoriasis pathogenesis","volume":"21","author":"Dombrowski","year":"2012","journal-title":"Exp Dermatol"},{"issue":"10","key":"10.1016\/j.advms.2015.07.011_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D33N39N8XM","article-title":"Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis","volume":"18","author":"Mudigonda","year":"2012","journal-title":"Dermatol Online J"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0535","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-012-8305-3","article-title":"Clinical and histologic diagnostic guidelines for psoriasis: a critical review","volume":"44","author":"Johnson","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7600","key":"10.1016\/j.advms.2015.07.011_bib0540","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bmj.39184.615150.802","article-title":"Psoriasis","volume":"334","author":"Jobling","year":"2007","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0545","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/art.34330","article-title":"A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis","volume":"64","author":"Yellin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0550","article-title":"A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection","volume":"13","author":"Jenh","year":"2012","journal-title":"BMC Immunol"},{"key":"10.1016\/j.advms.2015.07.011_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.68.1.1","article-title":"CXC chemokines in angiogenesis","volume":"68","author":"Belperio","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.advms.2015.07.011_bib0560","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.advms.2015.07.011_bib0565","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20021897","article-title":"An Alternatively Spliced Variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.advms.2015.07.011_bib0570","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2002-12-3945","article-title":"CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK\/p44\/p42 MAPK nor Akt\/PI-3 kinase","volume":"102","author":"Smit","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.advms.2015.07.011_bib0575","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/315672a0","article-title":"Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins","volume":"315","author":"Luster","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.advms.2015.07.011_bib0580","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.advms.2015.07.011_bib0585","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.182.1.155","article-title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo","volume":"182","author":"Angiolillo","year":"1995","journal-title":"J Exp Med"},{"issue":"21","key":"10.1016\/j.advms.2015.07.011_bib0590","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1161\/hc4601.098010","article-title":"Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection","volume":"104","author":"Melter","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0595","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0002-9440(10)64126-0","article-title":"Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection","volume":"158","author":"Agostini","year":"2001","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0600","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0952-7915(03)00103-1","article-title":"Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression","volume":"15","author":"Hancock","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.advms.2015.07.011_bib0605","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1523-1747.2000.00953.x","article-title":"Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice","volume":"114","author":"Sch\u00f6n","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2015.07.011_bib0610","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2013.04.001","article-title":"Autoinflammatory pustular neutrophilic diseases","volume":"31","author":"Naik","year":"2013","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0615","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/bjd.12631","article-title":"Bimodal immune activation in psoriasis","volume":"170","author":"Christophers","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0620","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ar7000815","article-title":"Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases","volume":"41","author":"Low","year":"2008","journal-title":"Acc Chem Res"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0625","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/mp3006962","article-title":"Use of folate-conjugated imaging agents to target alternatively activated macrophages in a murine model of asthma","volume":"10","author":"Shen","year":"2013","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.advms.2015.07.011_bib0630","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2362.2006.01739.x","article-title":"High- but not low-dose folic acid improves endothelial function in coronary artery disease","volume":"36","author":"Moat","year":"2006","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0635","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00011-011-0337-2","article-title":"Folic acid inhibits lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-\u03baB activation","volume":"60","author":"Feng","year":"2011","journal-title":"Inflamm Res"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0640","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/CS20070108","article-title":"Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease","volume":"113","author":"Schmidt","year":"2007","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0645","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.mehy.2008.09.058","article-title":"High-dose folate and dietary purines promote scavenging of peroxynitrite-derived radicals\u2013clinical potential in inflammatory disorders","volume":"73","author":"McCarty","year":"2009","journal-title":"Med Hypotheses"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0650","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0655","first-page":"405","article-title":"Towards rational treatment of severe psoriasis in alcoholics: report of two cases","volume":"9","author":"Aronson","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"1-2","key":"10.1016\/j.advms.2015.07.011_bib0660","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cyto.2006.03.012","article-title":"Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing","volume":"34","author":"Antonelli","year":"2006","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.advms.2015.07.011_bib0665","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1464-5491.2008.02577.x","article-title":"Serum Th1 (CX-CL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study","volume":"25","author":"Antonelli","year":"2008","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.advms.2015.07.011_bib0670","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2337\/diabetes.48.12.2309","article-title":"Autoantibodies to CD38 (ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets","volume":"48","author":"Pupilli","year":"1999","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0675","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2337\/diabetes.50.5.985","article-title":"Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets","volume":"50","author":"Antonelli","year":"2001","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0680","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","article-title":"CXCL10 and type 1 diabetes","volume":"25","author":"Antonelli","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"10.1016\/j.advms.2015.07.011_bib0685","doi-asserted-by":"crossref","first-page":"E413","DOI":"10.1210\/jc.2010-0923","article-title":"CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-{alpha} agonists secretion in graves\u2019 and normal thyrocytes","volume":"95","author":"Antonelli","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0690","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2265.1986.tb01658.x","article-title":"Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis?","volume":"24","author":"Martino","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0695","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.metabol.2010.02.002","article-title":"Cytokines (interferon-\u03b3 and tumor necrosis factor-\u03b1)-induced nuclear factor-\u03baB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone","volume":"60","author":"Antonelli","year":"2011","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0700","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0705","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/jc.2010-2905","article-title":"Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab6"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0710","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.autrev.2012.10.001","article-title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.advms.2015.07.011_bib0715","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0720","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis \u2013 a longitudinal study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0725","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-06-0591","article-title":"Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis","volume":"156","author":"Antonelli","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0730","first-page":"1809","article-title":"Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis","volume":"35","author":"Antonelli","year":"2008","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0735","first-page":"22","article-title":"High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis","volume":"27","author":"Antonelli","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.advms.2015.07.011_bib0740","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/08916930802170401","article-title":"High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis","volume":"41","author":"Antonelli","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.advms.2015.07.011_bib0745","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-14-121","article-title":"Interferon-inducible chemokines reflect severity and progression in sarcoidosis","volume":"14","author":"Su","year":"2013","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.advms.2015.07.011_bib0750","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/j.1572-0241.2008.02040.x","article-title":"High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection","volume":"103","author":"Antonelli","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0755","first-page":"e337","article-title":"Mixed cryoglobulinemia and thyroid autoimmune disorders","volume":"164","author":"Fallahi","year":"2013","journal-title":"Clin Ter"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0760","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2007.02.019","article-title":"B-cells and mixed cryoglobulinemia","volume":"7","author":"Ferri","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0765","first-page":"e305","article-title":"HCV-related autoimmune disorders in HCV chronic infection","volume":"164","author":"Ferrari","year":"2013","journal-title":"Clin Ter"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0770","first-page":"e437","article-title":"Hepatitis C virus and type 1 diabetes","volume":"164","author":"Fallahi","year":"2013","journal-title":"Clin Ter"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0775","first-page":"693","article-title":"Thyroid cancer in HCV-related mixed cryoglobulinemia patients","volume":"20","author":"Antonelli","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0780","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cyto.2008.01.002","article-title":"High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis","volume":"42","author":"Antonelli","year":"2008","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0785","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/thy.2006.0194","article-title":"Thyroid cancer in HCV-related chronic hepatitis patients: a case\u2013control study","volume":"17","author":"Antonelli","year":"2007","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0790","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.metabol.2008.04.023","article-title":"Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis","volume":"57","author":"Antonelli","year":"2008","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0795","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1677\/ERC-08-0337","article-title":"Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"16","author":"Antonelli","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.advms.2015.07.011_bib0800","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.biopha.2008.07.056","article-title":"Dedifferentiated thyroid cancer: a therapeutic challenge","volume":"62","author":"Antonelli","year":"2008","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0805","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2009.03.023","article-title":"3,5-Diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet","volume":"51","author":"Mollica","year":"2009","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0810","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-102-6-793","article-title":"Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates","volume":"102","author":"Pacini","year":"1985","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0815","doi-asserted-by":"crossref","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0820","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cyto.2012.04.042","article-title":"Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer","volume":"59","author":"Antonelli","year":"2012","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0825","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sder.2010.03.001","article-title":"New insights in the immunologic basis of psoriasis","volume":"29","author":"Nograles","year":"2010","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.advms.2015.07.011_bib0830","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.168.3.941","article-title":"Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques","volume":"168","author":"Gottlieb","year":"1988","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0835","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s004030050314","article-title":"Chemokine IP-10 expression in cultured human keratinocytes","volume":"290","author":"Boorsma","year":"1998","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0840","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/eji.200535243","article-title":"CD56brightCD16(\u2212) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation","volume":"36","author":"Ottaviani","year":"2006","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0845","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/jid.2009.349","article-title":"Possible roles of IL-27 in the pathogenesis of psoriasis","volume":"130","author":"Shibata","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2015.07.011_bib0850","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780242","article-title":"Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris","volume":"81","author":"Rottman","year":"2001","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0855","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mai.2001.114707","article-title":"Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines","volume":"107","author":"Giustizieri","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.advms.2015.07.011_bib0860","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mai.2003.114","article-title":"Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris","volume":"111","author":"Kakinuma","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0865","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.0022-202X.2005.23715.x","article-title":"Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases","volume":"124","author":"Wittmann","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0870","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1210\/en.2006-1639","article-title":"Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes","volume":"148","author":"Kanda","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0875","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/eji.200636420","article-title":"IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes","volume":"37","author":"Kanda","year":"2007","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.advms.2015.07.011_bib0880","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/08916934.2014.947476","article-title":"Circulating levels of chemokines in psoriasis","volume":"48","author":"Lima","year":"2015","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.advms.2015.07.011_bib0885","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jid.2012.313","article-title":"IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions","volume":"133","author":"Shibata","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0890","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/hmg\/ddt034","article-title":"Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis","volume":"22","author":"Johnston","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.advms.2015.07.011_bib0895","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1365-2133.2001.04220.x","article-title":"The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells","volume":"144","author":"Stoof","year":"2001","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0900","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0002-9440(10)64416-1","article-title":"Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo","volume":"161","author":"Giustizieri","year":"2002","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0905","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.advms.2015.07.011_bib0910","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.advms.2015.07.011_bib0915","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"10.1016\/j.advms.2015.07.011_bib0920","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14656566.2015.1034107","article-title":"Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis","volume":"16","author":"Abdulrahim","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.advms.2015.07.011_bib0925","doi-asserted-by":"crossref","first-page":"e107904","DOI":"10.1371\/journal.pone.0107904","article-title":"Inhibition of inflammatory and proliferative responses of human keratinocytes exposed to the sesquiterpene lactones dehydrocostuslactone and costunolide","volume":"9","author":"Scarponi","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.advms.2015.07.011_bib0930","doi-asserted-by":"crossref","first-page":"875403","DOI":"10.1155\/2013\/875403","article-title":"Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?","volume":"2013","author":"Seidel","year":"2013","journal-title":"Mediators Inflamm"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112615000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112615000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T14:11:39Z","timestamp":1718028699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112615000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1896112615000474"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2015.07.011","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL10 in psoriasis","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Urban & Partner Sp. z o.o.","name":"copyright","label":"Copyright"}]}}